2. Academic Validation
  3. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

  • MAbs. 2014 May-Jun;6(3):774-82. doi: 10.4161/mabs.28612.
Stevan Shaw 1,  Tim Bourne 1,  Chris Meier 1,  Bruce Carrington 1,  Rich Gelinas 2,  Alistair Henry 1,  Andrew Popplewell 1,  Ralph Adams 1,  Terry Baker 1,  Steve Rapecki 1,  Diane Marshall 1,  Adrian Moore 1,  Helen Neale 1,  Alastair Lawson 1
Affiliations

Affiliations

  • 1 UCB Pharma; Berkshire, UK.
  • 2 Institute for Systems Biology; Seattle, WA USA.
PMID: 24670876 DOI: 10.4161/mabs.28612
Abstract

Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, Cell Biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3", blocking the interaction with the signaling co-receptor gp130.

Keywords

IL-6; antibody; gp130; interleukin 6; neutralization; olokizumab; site 3; structure.

Figures
Products